New drug combo shows promise for Hard-to-Treat cancers

NCT ID NCT04170153

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new drug called tuvusertib, given alone or with another drug (niraparib), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage. About 161 participants are enrolled across multiple sites.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC OR LOCALLY ADVANCED UNRESECTABLE SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Addenbrooke's Hospital - Dept of Oncology

    Cambridge, United Kingdom

  • Beijing Cancer Hospital

    Beijing, China

  • Centro Integral Oncologico Clara Campal - Unidad de Fase I-Oncologica

    Madrid, Spain

  • Hospital Clinic de Barcelona - Servicio de Oncologia

    Barcelona, Spain

  • Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica

    Valencia, Spain

  • Hospital Universitari Vall d'Hebron - Oncology Dept.

    Barcelona, Spain

  • Mary Crowley Cancer Research Centers

    Dallas, Texas, 75230, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • NEXT Oncology

    Austin, Texas, 78758, United States

  • National Cancer Center Hospital - Dept of Experimental Therapeutics

    Chūōku, Japan

  • National Cancer Center Hospital East - Dept of Experimental Therapeutics

    Kashiwa-shi, Japan

  • Northern Centre for Cancer Care - Sir Bobby Robson Cancer Trials Research Centre

    Newcastle upon Tyne, United Kingdom

  • Royal Marsden Hospital - Dept of Oncology

    Sutton, United Kingdom

  • The Christie Hospital - Dept of Oncology

    Manchester, United Kingdom

  • The Methodist Hospital Research Institute

    Houston, Texas, 77030, United States

  • University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.